{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:01:24Z","timestamp":1782226884114,"version":"3.54.5"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with hematologic malignancies (HMs) are at a significantly higher risk of contracting COVID-19 and experiencing severe outcomes compared to individuals without HMs. This heightened risk is influenced by various factors, including the underlying malignancy, immunosuppressive treatments, and patient-related factors. Notably, immunosuppressive regimens commonly used for HM treatment can lead to the depletion of B cells and T cells, which is associated with increased COVID-19-related complications and mortality in these patients. As the pandemic transitions into an endemic state, it remains crucial to acknowledge and address the ongoing risk for individuals with HMs. In this review, we aim to summarize the current evidence to enhance our understanding of the impact of HMs on COVID-19 risks and outcomes, identify particularly vulnerable individuals, and emphasize the need for specialized clinical attention and management. Furthermore, the impaired immune response to COVID-19 vaccination observed in these patients underscores the importance of implementing additional mitigation strategies. This may include targeted prophylaxis and treatment with antivirals and monoclonal antibodies as indicated. To provide practical guidance and considerations, we present two illustrative cases to highlight the real-life challenges faced by physicians caring for patients with HMs, emphasizing the need for individualized management based on disease severity, type, and the unique circumstances of each patient.<\/jats:p>","DOI":"10.1007\/s10238-024-01381-5","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T13:10:44Z","timestamp":1717506644000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Managing and treating COVID-19 in patients with hematological malignancies: a narrative review and expert insights"],"prefix":"10.1007","volume":"24","author":[{"given":"Heng Joo","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaz Kamal","family":"Alata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quang The","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phu","family":"Huynh Duc Vinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing Yuan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieh Lee","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"key":"1381_CR1","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2022.114662","volume":"216","author":"R Suligowski","year":"2023","unstructured":"Suligowski R, Ciupa T. Five waves of the COVID-19 pandemic and green\u2013blue spaces in urban and rural areas in Poland. Environ Res. 2023;216: 114662.","journal-title":"Environ Res"},{"key":"1381_CR2","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.15492","volume":"11","author":"M Martella","year":"2023","unstructured":"Martella M, Peano A, Politano G, Onorati R, Gianino MM. Paediatric hospitalizations over three waves of COVID-19 (february 2020 to may 2021) in Italy: determinants and rates. PeerJ. 2023;11: e15492.","journal-title":"PeerJ"},{"key":"1381_CR3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12879-022-07941-y","volume":"23","author":"C Anscombe","year":"2023","unstructured":"Anscombe C, Lissauer S, Thole H, Rylance J, Dula D, Menyere M, et al. A comparison of four epidemic waves of COVID-19 in Malawi; an observational cohort study. BMC Infect Dis. 2023;23:79.","journal-title":"BMC Infect Dis"},{"key":"1381_CR4","doi-asserted-by":"crossref","first-page":"2155250","DOI":"10.1080\/22221751.2022.2155250","volume":"12","author":"K Miyashita","year":"2023","unstructured":"Miyashita K, Hozumi H, Furuhashi K, Nakatani E, Inoue Y, Yasui H, et al. Changes in the characteristics and outcomes of COVID-19 patients from the early pandemic to the delta variant epidemic: a nationwide population-based study. Emerg Microbes & Infect. 2023;12:2155250.","journal-title":"Emerg Microbes & Infect"},{"key":"1381_CR5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jiph.2022.11.024","volume":"16","author":"K Dhama","year":"2023","unstructured":"Dhama K, Nainu F, Frediansyah A, Yatoo Mohd I, Mohapatra RK, Chakraborty S, et al. Global emerging Omicron variant of SARS-CoV-2: impacts, challenges and strategies. J Infect Public Health. 2023;16:4\u201314.","journal-title":"J. Infect. Public Health"},{"issue":"23","key":"1381_CR6","first-page":"00580","volume":"S0006\u20133495","author":"Y-W Hsiao","year":"2023","unstructured":"Hsiao Y-W, Bray DJ, Taddese T, Jim\u00e9nez-Serratos G, Crain J. Structure adaptation in Omicron SARS-CoV-2\/hACE2: biophysical origins of evolutionary driving forces. Biophys J. 2023;S0006\u20133495(23):00580\u20135.","journal-title":"Biophys J"},{"key":"1381_CR7","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3390\/v15030618","volume":"15","author":"L Seyler","year":"2023","unstructured":"Seyler L, Van Nedervelde E, De Cock D, Mann C, Pien K, Allard SD, et al. Surfing the waves: differences in hospitalised COVID-19 patients across 4 variant waves in a Belgian University Hospital. Viruses. 2023;15:618.","journal-title":"Viruses"},{"key":"1381_CR8","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijid.2023.04.399","volume":"132","author":"H Tanaka","year":"2023","unstructured":"Tanaka H, Chubachi S, Asakura T, Namkoong H, Azekawa S, Otake S, et al. Characteristics and clinical effectiveness of COVID-19 vaccination in hospitalized patients in Omicron-dominated epidemic wave\u2014a nationwide study in Japan. Int J Infect Dis. 2023;132:84\u20138.","journal-title":"Int J Infect Dis"},{"key":"1381_CR9","doi-asserted-by":"crossref","first-page":"1185330","DOI":"10.3389\/fpubh.2023.1185330","volume":"11","author":"R Malaeb","year":"2023","unstructured":"Malaeb R, Haider A, Abdulateef M, Hameed M, Daniel U, Kabilwa G, et al. High mortality rates among COVID-19 intensive care patients in Iraq: insights from a retrospective cohort study at M\u00e9decins Sans Fronti\u00e8res supported hospital in Baghdad. Front Public Health. 2023;11:1185330.","journal-title":"Front Public Health"},{"key":"1381_CR10","unstructured":"Division of Cancer Prevention and Control, Centers for Disease Control and Prevention. Hematologic Cancer Incidence, Survival, and Prevalence [Internet]. Centers for Disease Control and Prevention. 2023 [cited 2023 Nov 9]. Available from: https:\/\/www.cdc.gov\/cancer\/uscs\/about\/data-briefs\/no30-hematologic-incidence-surv-prev.htm"},{"key":"1381_CR11","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2011.450","volume":"105","author":"A Smith","year":"2011","unstructured":"Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the haematological malignancy research network. Br J Cancer. 2011;105:1684\u201392.","journal-title":"Br J Cancer"},{"key":"1381_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00772-9","volume":"13","author":"N Zhang","year":"2023","unstructured":"Zhang N, Wu J, Wang Q, Liang Y, Li X, Chen G, et al. Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer J. 2023;13:1\u201313.","journal-title":"Blood Cancer J"},{"issue":"e279","key":"1381_CR13","first-page":"82","volume":"190","author":"V Shah","year":"2020","unstructured":"Shah V, Ko T, Zuckerman Ko M, Vidler J, Sharif S, Mehra V, et al. Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies King\u2019s College Hospital experience. Br J Haematol England. 2020;190(e279):82.","journal-title":"Br J Haematol England"},{"key":"1381_CR14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0267139","volume":"17","author":"A Zaki","year":"2022","unstructured":"Zaki A, Soomar SM, Khan DH, Shaharyar Sheikh H, Iftikhar R, Mir A, et al. Outcomes of COVID-19 infection in patients with hematological malignancies: a multicenter analysis from Pakistan. PLoS ONE. 2022;17: e0267139.","journal-title":"PLoS ONE"},{"key":"1381_CR15","doi-asserted-by":"crossref","first-page":"5966","DOI":"10.1182\/bloodadvances.2020003170","volume":"4","author":"WA Wood","year":"2020","unstructured":"Wood WA, Neuberg DS, Thompson JC, Tallman MS, Sekeres MA, Sehn LH, et al. Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH research collaborative data hub. Blood Adv. 2020;4:5966\u201375.","journal-title":"Blood Adv"},{"key":"1381_CR16","doi-asserted-by":"crossref","first-page":"7783","DOI":"10.1007\/s00520-022-07209-w","volume":"30","author":"JM Manzano","year":"2022","unstructured":"Manzano JM, Muthu M, Kheder E, Mohammed A, Halm J, Dickson K, et al. Hospitalization characteristics and outcomes of patients with cancer and COVID-19 at a comprehensive cancer center. Support Care Cancer. 2022;30:7783\u20138.","journal-title":"Support Care Cancer"},{"key":"1381_CR17","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1159\/000521000","volume":"68","author":"Y Asai","year":"2022","unstructured":"Asai Y, Nomoto H, Hayakawa K, Matsunaga N, Tsuzuki S, Terada M, et al. Comorbidities as risk factors for severe disease in hospitalized elderly COVID-19 patients by different age-groups in Japan. Gerontology. 2022;68:1027\u201337.","journal-title":"Gerontology"},{"key":"1381_CR18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","volume":"21","author":"W Liang","year":"2020","unstructured":"Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335\u20137.","journal-title":"Lancet Oncol"},{"key":"1381_CR19","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/jama.2022.2832","volume":"327","author":"A Gupta","year":"2022","unstructured":"Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Rodrigues Falci D, et al. Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2022;327:1236\u201346.","journal-title":"JAMA"},{"key":"1381_CR20","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100499","volume":"7","author":"L Castelo-Branco","year":"2022","unstructured":"Castelo-Branco L, Tsourti Z, Gennatas S, Rogado J, Sekacheva M, Vi\u00f1al D, et al. COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE). ESMO Open. 2022;7: 100499.","journal-title":"ESMO Open"},{"key":"1381_CR21","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41591-021-01386-7","volume":"27","author":"EM Bange","year":"2021","unstructured":"Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, et al. CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med. 2021;27:1280\u20139.","journal-title":"Nat Med"},{"key":"1381_CR22","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.24387","volume":"36","author":"A Naimi","year":"2022","unstructured":"Naimi A, Yashmi I, Jebeleh R, Imani Mofrad M, Azimian Abhar S, Jannesar Y, et al. Comorbidities and mortality rate in COVID-19 patients with hematological malignancies: a systematic review and meta-analysis. J Clin Lab Anal. 2022;36: e24387.","journal-title":"J Clin Lab Anal"},{"key":"1381_CR23","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S1470-2045(22)00273-X","volume":"23","author":"DJ Pinato","year":"2022","unstructured":"Pinato DJ, Aguilar-Company J, Ferrante D, Hanbury G, Bower M, Salazar R, et al. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre on COVID registry study. Lancet Oncol. 2022;23:865\u201375.","journal-title":"Lancet Oncol"},{"key":"1381_CR24","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.3390\/cancers15051497","volume":"15","author":"J Mart\u00ednez-L\u00f3pez","year":"2023","unstructured":"Mart\u00ednez-L\u00f3pez J, De La Cruz J, Gil-Manso R, Alegre A, Ortiz J, Llamas P, et al. COVID-19 severity and survival over time in patients with hematologic malignancies: a population-based registry study. Cancers. 2023;15:1497.","journal-title":"Cancers"},{"key":"1381_CR25","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1182\/blood.2021014124","volume":"139","author":"L Pagano","year":"2022","unstructured":"Pagano L, Salmanton-Garc\u00eda J, Marchesi F, L\u00f3pez-Garc\u00eda A, Lamure S, Itri F, et al. COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA. Blood. 2022;139:1588\u201392.","journal-title":"Blood"},{"key":"1381_CR26","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/j.thromres.2021.12.006","volume":"213","author":"M Levi","year":"2022","unstructured":"Levi M, van Es N. COVID-19 associated coagulopathy and thrombosis in cancer. Thromb Res. 2022;213:S72\u20136.","journal-title":"Thromb Res"},{"key":"1381_CR27","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1016\/j.clml.2021.12.011","volume":"22","author":"MR Cook","year":"2022","unstructured":"Cook MR, Dykes K, White K, Desale S, Agrawal R, Fernandez S, et al. Thrombotic and clinical outcomes in patients with hematologic malignancy and COVID-19. Clin Lymphoma Myeloma Leuk. 2022;22:e452\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1381_CR28","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1111\/jth.14849","volume":"18","author":"JM Connors","year":"2020","unstructured":"Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost. 2020;18:1559.","journal-title":"J Thromb Haemost"},{"key":"1381_CR29","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1182\/bloodadvances.2022007940","volume":"6","author":"A Cuker","year":"2022","unstructured":"Cuker A, Tseng EK, Sch\u00fcnemann HJ, Angchaisuksiri P, Blair C, Dane K, et al. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: march 2022 update on the use of anticoagulation in critically ill patients. Blood Adv. 2022;6:4975\u201382.","journal-title":"Blood Adv"},{"key":"1381_CR30","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3389\/fimmu.2017.00469","volume":"8","author":"A Hughes","year":"2017","unstructured":"Hughes A, Yong ASM. Immune effector recovery in chronic myeloid leukemia and treatment-free remission. Front Immunol. 2017;8:469.","journal-title":"Front Immunol"},{"key":"1381_CR31","first-page":"1429","volume":"2021","author":"Y Hu","year":"2019","unstructured":"Hu Y, Li Q, Hou M, Peng J, Yang X, Xu S. Magnitude and temporal trend of the chronic myeloid leukemia: on the basis of the global burden of disease study. JCO Glob Oncol. 2019;2021:1429\u201341.","journal-title":"JCO Glob Oncol"},{"key":"1381_CR32","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s11899-021-00653-1","volume":"16","author":"E Atallah","year":"2021","unstructured":"Atallah E, Sweet K. Treatment-free remission: the new goal in cml therapy. Curr Hematol Malig Rep. 2021;16:433\u20139.","journal-title":"Curr Hematol Malig Rep"},{"key":"1381_CR33","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s11912-021-01169-w","volume":"24","author":"N Delgado","year":"2022","unstructured":"Delgado N, Torres A. What do we currently know about chronic myeloid leukemia (CML) and COVID-19? Curr Oncol Rep. 2022;24:645\u201350.","journal-title":"Curr Oncol Rep"},{"key":"1381_CR34","doi-asserted-by":"crossref","first-page":"e1406","DOI":"10.1634\/theoncologist.2020-0141","volume":"25","author":"H Ludwig","year":"2020","unstructured":"Ludwig H, Novis Durie S, Meckl A, Hinke A, Durie B. Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment. Oncologist. 2020;25:e1406\u201313.","journal-title":"Oncologist"},{"key":"1381_CR35","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1186\/s12885-021-08280-y","volume":"21","author":"L Zhou","year":"2021","unstructured":"Zhou L, Yu Q, Wei G, Wang L, Huang Y, Hu K, et al. Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. BMC Cancer. 2021;21:606.","journal-title":"BMC Cancer"},{"key":"1381_CR36","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41408-021-00588-z","volume":"11","author":"J Martinez-Lopez","year":"2021","unstructured":"Martinez-Lopez J, Hernandez-Ibarburu G, Alonso R, Sanchez-Pina JM, Zamanillo I, Lopez-Mu\u00f1oz N, et al. Impact of COVID-19 in patients with multiple myeloma based on a global data network. Blood Cancer J. 2021;11:198.","journal-title":"Blood Cancer J"},{"key":"1381_CR37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-030-32482-7_1","volume-title":"Hodgkin lymphoma a comprehensive overview","author":"H Hjalgrim","year":"2020","unstructured":"Hjalgrim H, Jarrett RF. Epidemiology of hodgkin lymphoma. In: Engert A, Younes A, editors. Hodgkin lymphoma a comprehensive overview. Cham: Springer International Publishing; 2020. p. 3\u201323."},{"key":"1381_CR38","first-page":"432","volume":"34","author":"J Huang","year":"2020","unstructured":"Huang J, Rohatgi A, Schneider J, Braunstein M. Considerations for the management of oncology patients during the COVID-19 pandemic. Oncology (Williston Park). 2020;34:432\u201341.","journal-title":"Oncology (Williston Park)"},{"key":"1381_CR39","doi-asserted-by":"crossref","first-page":"312","DOI":"10.5501\/wjv.v10.i6.312","volume":"10","author":"V Bonuomo","year":"2021","unstructured":"Bonuomo V, Ferrarini I, Dell\u2019Eva M, Sbis\u00e0 E, Krampera M, Visco C. COVID-19 (SARS-CoV-2 infection) in lymphoma patients: a review. World J Virol. 2021;10:312\u201325.","journal-title":"World J Virol"},{"key":"1381_CR40","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1182\/bloodadvances.2021005691","volume":"6","author":"C Visco","year":"2022","unstructured":"Visco C, Marcheselli L, Mina R, Sassone M, Guidetti A, Penna D, et al. A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. Blood Adv. 2022;6:327\u201338.","journal-title":"Blood Adv"},{"key":"1381_CR41","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/bjh.17568","volume":"194","author":"P Harrington","year":"2021","unstructured":"Harrington P, Doores KJ, Radia D, O\u2019Reilly A, Lam HPJ, Seow J, et al. Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia. Br J Haematol. 2021;194:999\u20131006.","journal-title":"Br J Haematol"},{"key":"1381_CR42","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2020-140161","volume":"136","author":"D Rea","year":"2020","unstructured":"Rea D, Mauro MJ, Cortes JE, Jiang Q, Pagnano KB, Ongondi M, et al. COVID-19 in patients (pts) with chronic myeloid leukemia (CML): results from the International CML foundation (iCMLf) CML and COVID-19 (CANDID) study. Blood. 2020;136:46\u20137.","journal-title":"Blood"},{"key":"1381_CR43","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1038\/s41375-020-0904-z","volume":"34","author":"M Breccia","year":"2020","unstructured":"Breccia M, Abruzzese E, Bocchia M, Bonifacio M, Castagnetti F, Fava C, et al. Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy a campus CML survey. Leukemia. 2020;34:2260\u20131.","journal-title":"Leukemia"},{"key":"1381_CR44","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1038\/s41375-022-01633-x","volume":"36","author":"N Neparidze","year":"2022","unstructured":"Neparidze N, Wang R, Zeidan AM, Podoltsev NA, Shallis RM, Ma X, et al. Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period. Leukemia. 2022;36:2136\u20139.","journal-title":"Leukemia"},{"key":"1381_CR45","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.htct.2023.08.002","volume":"46","author":"M Garnica","year":"2023","unstructured":"Garnica M, Crusoe EDQ, Ribeiro G, Bittencourt R, Magalh\u00e3es RJP, Zanella KR, et al. COVID-19 in multiple myeloma patients: frequencies and risk factors for hospitalization, ventilatory support, intensive care admission and mortality\u2013cooperative registry from the Grupo Brasileiro de Mieloma Multiplo (GBRAM). Hematol Transfus Cell Ther. 2023;46:153\u201360.","journal-title":"Hematol Transfus Cell Ther."},{"key":"1381_CR46","doi-asserted-by":"crossref","first-page":"1059914","DOI":"10.3389\/fonc.2023.1059914","volume":"13","author":"Y Chu","year":"2023","unstructured":"Chu Y, Liu Y, Fang X, Jiang Y, Ding M, Ge X, et al. The epidemiological patterns of non-Hodgkin lymphoma: global estimates of disease burden, risk factors, and temporal trends. Front Oncol. 2023;13:1059914.","journal-title":"Front Oncol"},{"key":"1381_CR47","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311\u201320.","journal-title":"N Engl J Med"},{"key":"1381_CR48","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/s41375-020-0853-6","volume":"34","author":"W Li","year":"2020","unstructured":"Li W, Wang D, Guo J, Yuan G, Yang Z, Gale RP, et al. COVID-19 in persons with chronic myeloid leukaemia. Leukemia. 2020;34:1799\u2013804.","journal-title":"Leukemia"},{"key":"1381_CR49","volume-title":"Acute Myeloid Leukemia. StatPearls","author":"A Vakiti","year":"2024","unstructured":"Vakiti A, Mewawalla P. Acute Myeloid Leukemia. StatPearls. Florida: StatPearls Publishing; 2024."},{"key":"1381_CR50","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.3390\/cancers14153711","volume":"14","author":"F Modemann","year":"2022","unstructured":"Modemann F, Ghandili S, Schmiedel S, Weisel K, Bokemeyer C, Fiedler W. COVID-19 and adult acute leukemia: our knowledge in progress. Cancers. 2022;14:3711.","journal-title":"Cancers"},{"key":"1381_CR51","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.3390\/cancers15133346","volume":"15","author":"A Aureli","year":"2023","unstructured":"Aureli A, Marziani B, Venditti A, Sconocchia T, Sconocchia G. Acute lymphoblastic leukemia immunotherapy treatment: now, next, and beyond. Cancers (Basel). 2023;15:3346.","journal-title":"Cancers (Basel)"},{"key":"1381_CR52","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1002\/cncr.33160","volume":"126","author":"C Cattaneo","year":"2020","unstructured":"Cattaneo C, Daffini R, Pagani C, Salvetti M, Mancini V, Borlenghi E, et al. Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19. Cancer. 2020;126:5069\u201376.","journal-title":"Cancer"},{"key":"1381_CR53","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/jmv.26404","volume":"93","author":"TN Yigenoglu","year":"2021","unstructured":"Yigenoglu TN, Ata N, Altuntas F, Basc\u0131 S, Dal MS, Korkmaz S, et al. The outcome of COVID-19 in patients with hematological malignancy. J Med Virol. 2021;93:1099\u2013104.","journal-title":"J Med Virol"},{"key":"1381_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01428","author":"S Galimberti","year":"2020","unstructured":"Galimberti S, Petrini M, Barat\u00e8 C, Ricci F, Balducci S, Grassi S, et al. Tyrosine kinase inhibitors play an antiviral action in patients affected by chronic myeloid leukemia: a possible model supporting their use in the fight against SARS-CoV-2. Front Oncol. 2020. https:\/\/doi.org\/10.3389\/fonc.2020.01428.","journal-title":"Front Oncol"},{"key":"1381_CR55","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1099\/jgv.0.001047","volume":"99","author":"JM Sisk","year":"2018","unstructured":"Sisk JM, Frieman MB, Machamer CE. Coronavirus S protein-induced fusion is blocked prior to hemifusion by ABL kinase inhibitors. J Gen Virol. 2018;99:619\u201330.","journal-title":"J Gen Virol"},{"key":"1381_CR56","doi-asserted-by":"crossref","first-page":"8924","DOI":"10.1128\/JVI.01429-16","volume":"90","author":"CM Coleman","year":"2016","unstructured":"Coleman CM, Sisk JM, Mingo RM, Nelson EA, White JM, Frieman MB. Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and middle east respiratory syndrome coronavirus fusion. J Virol. 2016;90:8924\u201333.","journal-title":"J Virol"},{"key":"1381_CR57","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41408-020-00372-5","volume":"10","author":"J Mart\u00ednez-L\u00f3pez","year":"2020","unstructured":"Mart\u00ednez-L\u00f3pez J, Mateos MV, Encinas C, Sureda A, Hern\u00e1ndez-Rivas J, Lopez de la Gu\u00eda A, et al. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality. Blood Cancer J. 2020;10:103.","journal-title":"Blood Cancer J"},{"key":"1381_CR58","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1182\/blood.2020008150","volume":"136","author":"A Chari","year":"2020","unstructured":"Chari A, Samur MK, Martinez-Lopez J, Cook G, Biran N, Yong K, et al. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. 2020;136:3033\u201340.","journal-title":"Blood"},{"key":"1381_CR59","volume":"12","author":"Y Shang","year":"2022","unstructured":"Shang Y, Wang W, Liang Y, Kaweme NM, Wang Q, Liu M, et al. Development of a risk assessment model for early grade \u2265 3 infection during the first 3 months in patients newly diagnosed with multiple myeloma based on a multicenter real-world analysis in China. Front Oncol. 2022;12: 772015.","journal-title":"Front Oncol"},{"key":"1381_CR60","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/ejh.13502","volume":"105","author":"KH Susek","year":"2020","unstructured":"Susek KH, Gran C, Ljunggren H, Alici E, Nahi H. Outcome of COVID-19 in multiple myeloma patients in relation to treatment. Eur J Haematol. 2020;105:751\u20134.","journal-title":"Eur J Haematol"},{"key":"1381_CR61","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13045-020-00934-x","volume":"13","author":"B Wang","year":"2020","unstructured":"Wang B, Van Oekelen O, Mouhieddine TH, Del Valle DM, Richter J, Cho HJ, et al. A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. J Hematol Oncol. 2020;13:94.","journal-title":"J Hematol Oncol"},{"key":"1381_CR62","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00109-021-02114-x","volume":"100","author":"I von Metzler","year":"2022","unstructured":"von Metzler I, Campe J, Huenecke S, Raab MS, Goldschmidt H, Schubert R, et al. COVID-19 in multiple-myeloma patients: cellular and humoral immunity against SARS-CoV-2 in a short- and long-term view. J Mol Med (Berl). 2022;100:463\u201370.","journal-title":"J Mol Med (Berl)"},{"key":"1381_CR63","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/medicina59010053","volume":"59","author":"HY Ibrahem","year":"2022","unstructured":"Ibrahem HY, Aly DH, Warda AEA, Farahat RA, Youssef RM, Abdelhamid MH, et al. Efficacy of tocilizumab in management of COVID-19 patients admitted to intensive care units: a multicenter retrospective cohort study. Medicina. 2022;59:53.","journal-title":"Medicina"},{"key":"1381_CR64","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.3390\/cancers15143598","volume":"15","author":"R Zheng","year":"2023","unstructured":"Zheng R, Mieth K, Bennett C, Miller C, Anderson LD, Chen M, et al. Clinical features and risk stratification of multiple myeloma patients with COVID-19. Cancers (Basel). 2023;15:3598.","journal-title":"Cancers (Basel)"},{"key":"1381_CR65","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1007\/s00277-021-04594-w","volume":"100","author":"M Krejci","year":"2021","unstructured":"Krejci M, Pour L, Adam Z, Sandecka V, Stork M, Sevcikova S, et al. Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience. Ann Hematol. 2021;100:2541\u20136.","journal-title":"Ann Hematol"},{"key":"1381_CR66","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16874","author":"G Cook","year":"2020","unstructured":"Cook G, John Ashcroft A, Pratt G, Popat R, Ramasamy K, Kaiser M, et al. Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. Br J Haematol. 2020. https:\/\/doi.org\/10.1111\/bjh.16874.","journal-title":"Br J Haematol"},{"key":"1381_CR67","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.clml.2023.01.006","volume":"23","author":"H Ehsan","year":"2023","unstructured":"Ehsan H, Britt A, Voorhees PM, Paul B, Bhutani M, Varga C, et al. Retrospective review of outcomes of multiple myeloma (MM) patients with COVID-19 infection (two-center study). Clin Lymphoma Myeloma Leuk. 2023;23:273\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1381_CR68","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1158\/2643-3230.BCD-20-0102","volume":"1","author":"M Hultcrantz","year":"2020","unstructured":"Hultcrantz M, Richter J, Rosenbaum CA, Patel D, Smith EL, Korde N, et al. COVID-19 infections and clinical outcomes in patients with multiple myeloma in New York city: a cohort study from five academic centers. Blood Cancer Discov. 2020;1:234\u201343.","journal-title":"Blood Cancer Discov"},{"key":"1381_CR69","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s12254-021-00775-5","volume":"15","author":"P T\u0131\u011fl\u0131o\u011flu","year":"2022","unstructured":"T\u0131\u011fl\u0131o\u011flu P, Albayrak M, T\u0131\u011fl\u0131o\u011flu M, \u00d6zt\u00fcrk HBA, Aras MR, Sa\u011flam B, et al. The outcome of COVID-19 in patients with hematological malignancy. Memo. 2022;15:83\u20139.","journal-title":"Memo"},{"key":"1381_CR70","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s15010-022-01869-w","volume":"50","author":"A Oliva","year":"2022","unstructured":"Oliva A, Curtolo A, Volpicelli L, Cancelli F, Borrazzo C, Cogliati Dezza F, et al. Clinical course of Coronavirus Disease-19 in patients with haematological malignancies is characterized by a longer time to respiratory deterioration compared to non-haematological ones: results from a case-control study. Infection. 2022;50:1373\u201382.","journal-title":"Infection"},{"key":"1381_CR71","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/ajh.26209","volume":"96","author":"R Dul\u00e9ry","year":"2021","unstructured":"Dul\u00e9ry R, Lamure S, Delord M, Di Blasi R, Chauchet A, Hueso T, et al. Prolonged in-hospital stay and higher mortality after COVID-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am J Hematol. 2021;96:934\u201344.","journal-title":"Am J Hematol"},{"key":"1381_CR72","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13045-021-01177-0","volume":"14","author":"L Pagano","year":"2021","unstructured":"Pagano L, Salmanton-Garc\u00eda J, Marchesi F, Busca A, Corradini P, Hoenigl M, et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol. 2021;14:168.","journal-title":"J Hematol Oncol"},{"key":"1381_CR73","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3324\/haematol.2022.280847","volume":"108","author":"F Marchesi","year":"2022","unstructured":"Marchesi F, Salmanton-Garc\u00eda J, Emarah Z, Piukovics K, Nucci M, L\u00f3pez-Garc\u00eda A, et al. COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the european hematology Association survey (EPICOVIDEHA). Haematologica. 2022;108:22\u201333.","journal-title":"Haematologica"},{"key":"1381_CR74","volume":"9","author":"JD Goldman","year":"2021","unstructured":"Goldman JD, Robinson PC, Uldrick TS, Ljungman P. COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies. J Immunother Cancer. 2021;9: e002630.","journal-title":"J Immunother Cancer"},{"key":"1381_CR75","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.annonc.2021.02.024","volume":"32","author":"P Grivas","year":"2021","unstructured":"Grivas P, Khaki AR, Wise-Draper TM, French B, Hennessy C, Hsu C-Y, et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and cancer consortium. Ann Oncol. 2021;32:787\u2013800.","journal-title":"Ann Oncol"},{"key":"1381_CR76","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jamaoncol.2021.5148","volume":"8","author":"M Chavez-MacGregor","year":"2022","unstructured":"Chavez-MacGregor M, Lei X, Zhao H, Scheet P, Giordano SH. Evaluation of COVID-19 mortality and adverse outcomes in us patients with or without cancer. JAMA Oncol. 2022;8:69\u201378.","journal-title":"JAMA Oncol"},{"key":"1381_CR77","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.0130","volume":"5","author":"C V\u00e1rnai","year":"2022","unstructured":"V\u00e1rnai C, Palles C, Arnold R, Curley HM, Purshouse K, Cheng VWT, et al. Mortality among adults with cancer undergoing chemotherapy or immunotherapy and infected with COVID-19. JAMA Netw Open. 2022;5: e220130.","journal-title":"JAMA Netw Open"},{"key":"1381_CR78","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1200\/JCO.21.01074","volume":"39","author":"N Sharafeldin","year":"2021","unstructured":"Sharafeldin N, Bates B, Song Q, Madhira V, Yan Y, Dong S, et al. Outcomes of COVID-19 in patients with cancer: report from the national COVID cohort collaborative (N3C). J Clin Oncol. 2021;39:2232\u201346.","journal-title":"J Clin Oncol"},{"key":"1381_CR79","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1158\/2159-8290.CD-21-1033","volume":"12","author":"CY Lee","year":"2022","unstructured":"Lee CY, Shah MK, Hoyos D, Solovyov A, Douglas M, Taur Y, et al. Prolonged SARS-CoV-2 infection in patients with lymphoid malignancies. Cancer Discov. 2022;12:62\u201373.","journal-title":"Cancer Discov"},{"key":"1381_CR80","doi-asserted-by":"crossref","first-page":"2102828","DOI":"10.1183\/13993003.02828-2021","volume":"59","author":"GS Cheng","year":"2022","unstructured":"Cheng GS, Evans SE. The paradox of immunosuppressants and COVID-19. Eur Respir J. 2022;59:2102828.","journal-title":"Eur Respir J"},{"key":"1381_CR81","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.cmi.2020.10.021","volume":"27","author":"M Ripa","year":"2021","unstructured":"Ripa M, Galli L, Poli A, Oltolini C, Spagnuolo V, Mastrangelo A, et al. Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. Clin Microbiol Infect. 2021;27:451\u20137.","journal-title":"Clin Microbiol Infect"},{"key":"1381_CR82","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hon.3048","volume":"40","author":"P Zappasodi","year":"2022","unstructured":"Zappasodi P, Cattaneo C, Valeria Ferretti V, Mina R, Jos\u00e9 Mar\u00eda Ferreri A, Merli F, et al. Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: a report from the ITA-HEMA-COV. Hematol Oncol. 2022;40:846\u201356.","journal-title":"Hematol Oncol"},{"key":"1381_CR83","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.3390\/biomedicines10123069","volume":"10","author":"IC Casetti","year":"2022","unstructured":"Casetti IC, Borsani O, Rumi E. COVID-19 in patients with hematologic diseases. Biomedicines. 2022;10:3069.","journal-title":"Biomedicines"},{"key":"1381_CR84","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/S1470-2045(21)00573-8","volume":"22","author":"DJ Pinato","year":"2021","unstructured":"Pinato DJ, Tabernero J, Bower M, Scotti L, Patel M, Colomba E, et al. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the on covid retrospective, multicentre registry study. Lancet Oncol. 2021;22:1669\u201380.","journal-title":"Lancet Oncol"},{"key":"1381_CR85","doi-asserted-by":"crossref","first-page":"988536","DOI":"10.3389\/fimmu.2022.988536","volume":"13","author":"S Chen","year":"2022","unstructured":"Chen S, Guan F, Candotti F, Benlagha K, Camara NOS, Herrada AA, et al. The role of B cells in COVID-19 infection and vaccination. Front Immunol. 2022;13:988536.","journal-title":"Front Immunol"},{"key":"1381_CR86","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103896","volume":"181","author":"N Shah","year":"2023","unstructured":"Shah N, Mustafa SS, Vinh DC. Management of secondary immunodeficiency in hematological malignancies in the era of modern oncology. Crit Rev Oncol Hematol. 2023;181: 103896.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1381_CR87","first-page":"2050313X2211485","volume":"11","author":"JE Barahona-Correa","year":"2023","unstructured":"Barahona-Correa JE, Rueda-Ortiz C, L\u00f3pez M-J, Gualtero S, Arevalo-Zambrano M. COVID-19 infection during blinatumomab therapy: is safety a dilemma? SAGE Open Med Case Rep. 2023;11:2050313X221148548.","journal-title":"SAGE Open Med Case Rep"},{"key":"1381_CR88","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/s41375-022-01578-1","volume":"36","author":"S Cesaro","year":"2022","unstructured":"Cesaro S, Ljungman P, Mikulska M, Hirsch HH, von Lilienfeld-Toal M, Cordonnier C, et al. Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). Leukemia. 2022;36:1467.","journal-title":"Leukemia"},{"key":"1381_CR89","first-page":"102553","volume":"71","author":"J Salmanton-Garc\u00eda","year":"2024","unstructured":"Salmanton-Garc\u00eda J, Marchesi F, Farina F, Weinbergerov\u00e1 B, Itri F, D\u00e1vila-Valls J, et al. Decoding the historical tale: COVID-19 impact on haematological malignancy patients\u2014EPICOVIDEHA insights from 2020 to 2022. E Clin Med. 2024;71:102553.","journal-title":"E Clin Med"},{"key":"1381_CR90","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1038\/s41375-023-01938-5","volume":"37","author":"S Cesaro","year":"2023","unstructured":"Cesaro S, Mikulska M, Hirsch HH, Styczynski J, Meylan S, Cordonnier C, et al. Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9). Leukemia. 2023;37:1933.","journal-title":"Leukemia"},{"key":"1381_CR91","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/bloodadvances.2021005094","volume":"5","author":"C Perry","year":"2021","unstructured":"Perry C, Luttwak E, Balaban R, Shefer G, Morales MM, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Adv. 2021;5:3053\u201361.","journal-title":"Blood Adv"},{"key":"1381_CR92","doi-asserted-by":"crossref","first-page":"E312","DOI":"10.1002\/ajh.26626","volume":"97","author":"O Blennow","year":"2022","unstructured":"Blennow O, Salmanton-Garc\u00eda J, Nowak P, Itri F, Van Doesum J, L\u00f3pez-Garc\u00eda A, et al. Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: an EPICOVIDEHA survey report. Am J Hematol. 2022;97:E312\u20137.","journal-title":"Am J Hematol"},{"key":"1381_CR93","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/hon.2916","volume":"39","author":"G Del Poeta","year":"2021","unstructured":"Del Poeta G, Bomben R, Polesel J, Rossi FM, Pozzo F, Zaina E, et al. COVID-19 vaccination: evaluation of risk for protection failure in chronic lymphocytic leukemia patients. Hematol Oncol. 2021;39:712\u20134.","journal-title":"Hematol Oncol"},{"key":"1381_CR94","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.annonc.2021.10.014","volume":"33","author":"C Corti","year":"2022","unstructured":"Corti C, Antonarelli G, Scott\u00e9 F, Spano JP, Barri\u00e8re J, Michot JM, et al. Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review. Ann Oncol. 2022;33:158\u201368.","journal-title":"Ann Oncol"},{"key":"1381_CR95","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ccell.2021.06.002","volume":"39","author":"A Thakkar","year":"2021","unstructured":"Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell. 2021;39:1081-1090.e2.","journal-title":"Cancer Cell"},{"key":"1381_CR96","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/ejh.13722","volume":"108","author":"M Morawska","year":"2022","unstructured":"Morawska M. Reasons and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia. Eur J Haematol. 2022;108:91\u20138.","journal-title":"Eur J Haematol"},{"key":"1381_CR97","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.ccell.2021.09.015","volume":"39","author":"A Aleman","year":"2021","unstructured":"Aleman A, Upadhyaya B, Tuballes K, Kappes K, Gleason CR, Beach K, et al. Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma. Cancer Cell. 2021;39:1442\u20134.","journal-title":"Cancer Cell"},{"key":"1381_CR98","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ccell.2021.06.014","volume":"39","author":"OV Oekelen","year":"2021","unstructured":"Oekelen OV, Gleason CR, Agte S, Srivastava K, Beach KF, Aleman A, et al. Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. Cancer Cell. 2021;39:1028\u201330.","journal-title":"Cancer Cell"},{"key":"1381_CR99","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.clml.2023.03.002","volume":"23","author":"JE Wiedmeier-Nutor","year":"2023","unstructured":"Wiedmeier-Nutor JE, Iqbal M, Rosenthal AC, Bezerra ED, Garcia-Robledo JE, Bansal R, et al. Response to COVID-19 vaccination post-CAR T therapy in patients with non-Hodgkin lymphoma and multiple myeloma. Clin Lymphoma Myeloma Leuk. 2023;23:456\u201362.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1381_CR100","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40164-023-00426-x","volume":"12","author":"T Zhang","year":"2023","unstructured":"Zhang T, Tian W, Wei S, Lu X, An J, He S, et al. Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era. Exp Hematol Oncol. 2023;12:66.","journal-title":"Exp Hematol Oncol"},{"key":"1381_CR101","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejca.2022.11.030","volume":"181","author":"N Giesen","year":"2023","unstructured":"Giesen N, Busch E, Schalk E, Beutel G, R\u00fcthrich MM, Hentrich M, et al. AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants. Eur J Cancer. 2023;181:102\u201318.","journal-title":"Eur J Cancer"},{"key":"1381_CR102","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.3390\/curroncol29060315","volume":"29","author":"C Owen","year":"2022","unstructured":"Owen C, Robinson S, Christofides A, Sehn LH. A canadian perspective: monoclonal antibodies for pre- and post-exposure protection from COVID-19 in vulnerable patients with hematological malignancies. Curr Oncol. 2022;29:3940\u20139.","journal-title":"Curr Oncol"},{"key":"1381_CR103","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","volume":"386","author":"MJ Levin","year":"2022","unstructured":"Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, et al. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of COVID-19. N Engl J Med. 2022;386:2188\u2013200.","journal-title":"N Engl J Med"},{"key":"1381_CR104","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1056\/NEJMoa2109682","volume":"385","author":"MP O\u2019Brien","year":"2021","unstructured":"O\u2019Brien MP, Forleo-Neto E, Musser BJ, Isa F, Chan KC, Sarkar N, et al. Subcutaneous REGEN-COV antibody combination to prevent COVID-19. N Engl J Med. 2021;385:1184\u201395.","journal-title":"N Engl J Med"},{"key":"1381_CR105","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ccell.2022.05.007","volume":"40","author":"R Stuver","year":"2022","unstructured":"Stuver R, Shah GL, Korde NS, Roeker LE, Mato AR, Batlevi CL, et al. Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies. Cancer Cell. 2022;40:590\u20131.","journal-title":"Cancer Cell"},{"key":"1381_CR106","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1093\/cid\/ciac443","volume":"76","author":"R Najjar-Debbiny","year":"2022","unstructured":"Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, et al. Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clin Infect Dis. 2022;76:e342\u20139.","journal-title":"Clin Infect Dis"},{"key":"1381_CR107","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","volume":"386","author":"RL Gottlieb","year":"2022","unstructured":"Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, et al. Early remdesivir to prevent progression to severe COVID-19 in outpatients. N Engl J Med. 2022;386:305\u201315.","journal-title":"N Engl J Med"},{"key":"1381_CR108","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med. 2022;386:1397\u2013408.","journal-title":"N Engl J Med"},{"key":"1381_CR109","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","volume":"386","author":"A Jayk Bernal","year":"2022","unstructured":"Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, et al. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. N Engl J Med. 2022;386:509\u201320.","journal-title":"N Engl J Med"},{"key":"1381_CR110","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejca.2020.09.009","volume":"140","author":"N Giesen","year":"2020","unstructured":"Giesen N, Sprute R, R\u00fcthrich M, Khodamoradi Y, Mellinghoff SC, Beutel G, et al. Evidence-based management of COVID-19 in cancer patients: guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Eur J Cancer. 2020;140:86\u2013104.","journal-title":"Eur J Cancer"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-024-01381-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-024-01381-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-024-01381-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T17:20:23Z","timestamp":1732987223000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-024-01381-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":110,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1381"],"URL":"https:\/\/doi.org\/10.1007\/s10238-024-01381-5","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,4]]},"assertion":[{"value":"8 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Following the International Committee of Medical Journal Editors\u2019 (ICMJE) guidelines, Heng Joo Ng and Chieh Lee Wong report receiving consulting fees and honoraria for lectures and presentations from AstraZeneca. Quang The Nguyen reports receiving consulting fees from AstraZeneca. Phu\u00a0Huynh Duc Vinh  reports receiving consulting fees and honoraria for lectures and presentations from AstraZeneca and Novartis. Maaz Kamal Alata reports receiving honoraria for lectures and presentations for AstraZeneca, Pfizer, and Astellas Pharma. Additionally, he reports receiving meeting attendance support from Astellas Pharma, NewBridge Pharmaceuticals, Merck, and Gilead. Jing Yuan Tan has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants, or patents received or pending, or royalties.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"119"}}